What are GLP-1 medications?
GLP-1 receptor agonists are a class of medications that mimic a naturally occurring gut hormone (glucagon-like peptide-1) that regulates appetite, blood sugar, and satiety. Originally developed to treat type 2 diabetes, they have become the most consistently effective pharmacologic tools for weight management currently available.
Semaglutide and tirzepatide are the most widely prescribed. Tirzepatide is a dual agonist that also activates the GIP receptor, which contributes to its stronger metabolic effect in most patients.
How they work
GLP-1 agonists work through several complementary mechanisms:
- Delayed gastric emptying: food stays in the stomach longer, prolonging fullness after meals.
- Central appetite modulation: signals in the brain that reduce food-seeking behavior and cravings.
- Improved insulin sensitivity: blood sugar stabilizes, reducing the reactive hunger that drives snacking.
The result is that patients eat less without white-knuckling through it. Most describe reduced “food noise” — the constant background awareness of the next meal — within the first several weeks.
Who they may help
GLP-1s are typically appropriate for adults with:
- BMI ≥ 30, or
- BMI ≥ 27 with a weight-related condition (hypertension, prediabetes, sleep apnea, joint disease), or
- Type 2 diabetes
They are not first-line for cosmetic weight loss in patients with normal BMI, and they are not appropriate substitutes for foundational lifestyle change. They work best when combined with a physician-guided nutrition plan and resistance training.
What to expect
Treatment typically starts at a low dose and titrates up over 8–16 weeks. Most patients begin to see appetite changes within the first two weeks. Weight loss is gradual and continues for 12–18 months on therapy. Expected weight loss ranges from roughly 10% (semaglutide) to 15–20% (tirzepatide) of starting body weight on average, though individual response varies widely.
Side effects
The most common side effects are gastrointestinal — nausea, constipation, occasional reflux, and reduced appetite (which is largely the therapeutic effect). These are typically most pronounced during dose escalation and improve as the body adjusts. Slow titration is our default approach for this reason.
Serious side effects are uncommon but include pancreatitis, gallbladder issues, and rare cases of severe gastroparesis. We screen carefully at baseline and monitor throughout.
Preserving muscle
Rapid weight loss on any protocol tends to cost lean mass along with fat, and GLP-1s are no exception. We aggressively recommend resistance training 2–3 times weekly and adequate protein (typically 0.7–1.0 g per pound of goal body weight) for anyone on these medications. Muscle preservation is not optional — it protects metabolic rate and long-term outcomes.
After treatment
Weight regain after stopping is common, particularly if the underlying eating patterns and exercise habits were not durably changed. We build maintenance into the plan from the start, including the possibility of long-term low-dose therapy for patients who need it.
Common questions
How long do I stay on it? For most patients, at least 12–18 months. Some stay on low-dose maintenance long-term.
Do I need to change my diet? The medication reduces hunger, but the food choices during that reduced-hunger window determine whether the loss is muscle or fat, and whether it’s sustainable.
What about compounded versions? We use only FDA-approved formulations from licensed pharmacies. Compounded semaglutide has significant quality and safety concerns.
Next steps
If weight has been a persistent issue and lifestyle changes alone haven’t been enough, a proper medical evaluation is the right first step. We start with metabolic labs, discuss goals honestly, and build a plan that fits your life.